EUVIMEDEUVIMED entdecken
Crossref

Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib

Guangzhi Ma, Dongsheng Wang, Yunfu Deng, Weijia Huang, Yifan Zhai, Shi-Yong Sun

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Guangzhi Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of He…. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Acrylamides, Aniline Compounds, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Emory University Winship Cancer Institute, Ascentage Pharma, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) using mutation-selective third generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success. However, the emergence of acquired resistance is an inevitable challenge that limits the long-term remission of patients. Thus, it is critical to manage acquired resistance to osimertinib to maximize its therapeutic efficacy for long-term therapeutic benefit. To this end, taking an early intervention to delay or even prevent the emergence of acquired resistance to osimertinib offers an effective strategy. The current study suggests an effective strategy to do so through directly targeting the intrinsic apoptotic pathway via Mcl-1 inhibition. Several EGFR-mutant NSCLC cell lines with primary resistance to osimertinib possessed elevated levels of Mcl-1, which were no longer reduced by osimertinib. The combination of osimertinib with an Mcl-1 inhibitor (e.g., S63845 or APG3526) synergistically decreased the survival of these resistant cell lines with enhanced induction of apoptosis including augmentation of mitochondrial cytochrome C and Smac release. This combination effectively eliminated senescence-like drug-tolerant persister cells, which had elevated Mcl-1 levels, and abrogated emergence of acquired resistance to osimertinib as demonstrated using both in vitro cell culture and in vivo animal models. Collectively, these results convincingly demonstrate a novel and effective strategy for delaying the emergence of acquired resistance to osimertinib by targeting activation of the intrinsic apoptotic pathway through Mcl-1 inhibition, warranting further clinical validation of this strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Cell Leukemia Sequence 1 ProteinAcrylamidesAniline CompoundsDrug Resistance, NeoplasmLung NeoplasmsApoptosisCarcinoma, Non-Small-Cell LungHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysMiceErbB ReceptorsProtein Kinase InhibitorsMutationMice, NudeSignal TransductionDrug SynergismAntineoplastic Combined Chemotherapy ProtocolsIndolesPyrimidinesThiophenes

Stichwörter der Autor:innen

ApoptosisEGFR inhibitorsLung cancerMcl-1Resistance delay

Substanzen

osimertinibMyeloid Cell Leukemia Sequence 1 ProteinAcrylamidesAniline CompoundsMCL1 protein, humanErbB ReceptorsEGFR protein, humanS63845Protein Kinase InhibitorsIndoles

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Hematology and Medical Oncology, Emory University School of Medicine and…
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichua…
  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Ascentage Pharma (Suzhou) Co., Ltd, Suzhou, Jiangsu, China.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. Electronic address: ssun@emory.edu.

Förderung

  • Emory University Winship Cancer Institute
  • Ascentage Pharma
  • National Natural Science Foundation of China

Zitieren

APA

Ma, G., Wang, D., Deng, Y., Huang, W., Zhai, Y., & Sun, S. Y. (2025). Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217962

Vancouver

Ma G, Wang D, Deng Y, Huang W, Zhai Y, Sun SY. Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217962

BibTeX
@article{Ma2025,
  author = {Ma, Guangzhi and Wang, Dongsheng and Deng, Yunfu and Huang, Weijia and Zhai, Yifan and Sun, Shi-Yong},
  title = {Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217962}
}
Kostenlos starten →